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ABSTRACT
Background: MGL_1304 secreted by Malassezia globosa is contained in human sweat and induces hista-
mine release from basophils in patients with atopic dermatitis (AD) at a high positive rate. The aims of this study
were to establish the enzyme-linked immunosorbent assay (ELISA) measuring specific immunoglobulins
against MGL_1304 and to investigate the levels of these immunoglobulins in sera of patients with various aller-
gic diseases.
Methods: Purified MGL_1304 from human sweat (QRX) and recombinant MGL_1304 (rMGL_1304) were pre-
pared for ELISA. To quantify the amount of MGL_1304-specific immunoglobulins, the standard serum was cre-
ated by pooling sera of 20 patients with AD whose basophils released histamine in response to QRX. A mono-
clonal antibody which exhibited the highest neutralizing ability against QRX was established as Smith-2, and
used as a capture antibody for the assay of QRX-specific IgE. A total of 156 subjects [normal controls (n = 23),
AD (n = 63), cholinergic urticaria (CU) (n = 24), bronchial asthma (n = 32), and allergic rhinitis (n = 14)] were en-
rolled in this study.
Results: ELISA methods to quantify the specific IgE, IgG and IgG4 against MGL_1304 in sera were success-
fully established. Levels of QRX-specific IgE in sera of patients with AD and CU were significantly higher than
those of normal controls. Moreover, the levels of QRX-specific IgE and rMGL_1304-specific IgE in patients with
AD were significantly correlated with their disease severities.
Conclusions: These ELISA methods to quantify the specific immunoglobulins against MGL_1304 are easy
and useful means to assess allergy to MGL_1304. MGL_1304 contained in sweat is an important antigen for
patients with AD and CU.
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INTRODUCTION
Atopic dermatitis (AD) is an inflammatory pruritic,
chronic or chronically relapsing skin disease occur-
ring often in families with other atopic diseases.1-3
The involvement of IgE has been suggested as an im-
portant factor in the pathogenesis of AD, as in other
atopic diseases, such as asthma or allergic rhinitis.
Moreover, high levels of total IgE in sera of patients
with AD, and several reports presenting the effective-
ness of omalizumab for AD4,5 enforce the importance
of IgE in AD. Recently, filaggrin shed light on the de-
velopment of AD,6 but mutations of filaggrin are also
detected in patients with ichthyosis vulgaris without
AD. Moreover, only 15% of mild-to-moderate AD and
50% of moderate-to-severe AD cases have revealed
filaggrin mutations.7 Thus, precise role of IgE in the
pathogenesis of AD remains to be investigated.
Numerous triggering factors, such as irritants,
aeroallergens, food, microbial organisms, and sweat-
ing, are also known to be involved in the development
andor the aggravation of AD.3 We and other authors
Allergology International. 2014;63:83-93
ORIGINAL ARTICLE
1Department of Dermatology, 3Department of Molecular and Inter-
nal Medicine, Graduate School of Biomedical and Health Sci-
ences, Hiroshima University and 2Faculty of Human Science, Hiro-
shima Bunkyo Women’s University, Hiroshima, Japan.
Conflict of interest: No potential conflict of interest was disclosed.
Correspondence: Michihiro Hide, MD,PhD, Department of Derma-
tology, Graduate School of Biomedical and Health Sciences, Hiro-
shima University, 1−2−3 Kasumi, Minami-ku, Hiroshima 734−
8551, Japan.
Email: ed1h−w1de−road@hiroshima−u.ac.jp
Received 1 August 2013. Accepted for publication 3 October
2013.
2014 Japanese Society of Allergology
DOI: 10.2332allergolint.13-OA-0611
Hiragun M et al.
84 Allergology International Vol 63, No1, 2014 www.jsaweb.jp
reported that skin test with autologous sweat was
positive in the majority of patients with AD,8-10 and
clinical symptoms of children with AD significantly
improved during the summer if they took showers at
schools.11,12 Moreover, we previously revealed that
semi-purified sweat antigen induced histamine re-
lease from the basophils of 77% patients of AD13 and
66% patients of cholinergic urticaria (CU),14 and the
histamine release by sweat antigen was mediated by
specific IgE.9,13 Finally, we extensively purified hista-
mine release activity of the semi-purified sweat anti-
gen by a combination of various chromatographies
and identified a putative protein, MGL_1304 of
Malassezia globosa (M. globosa), as a major allergen in
human sweat.15 MGL_1304 induced histamine re-
lease of basophils obtained from the majority of pa-
tients with AD.15 In Japan, a commercial histamine re-
lease test (HRT) against sweat containing MGL_1304
has been available since 2010. However, HRT needs
fresh blood cells of patients and its results are qualita-
tive rather than quantitative. In the present study, to
overcome the disadvantages of HRT, we established
enzyme-linked immunosorbent assays (ELISAs) to
measure specific IgE against native MGL_1304 col-
lected from human sweat (QRX) and recombinant
MGL_1304 (rMGL_1304) by using sera of patients
with AD and other allergic diseases.
METHODS
PATIENTS AND ETHICS
A total of 156 subjects were enrolled in this study.
Sixty-three patients with AD (36 men and 27 women;
0-65 years of age, mean ± SD: 29.9 ± 11.5), 24 patients
with cholinergic urticaria (CU) and no history of AD
(14 men and 10 women; 7-65 years of age, mean ±
SD: 24.0 ± 13.7) and 32 patients with bronchial
asthma (BA) and without AD (15 men and 17 women;
20-82 years of age, mean ± SD: 54.6 ± 16.0) who vis-
ited Hiroshima University Hospital were included in
this study. Fourteen patients with allergic rhinitis
(AR) without other allergic diseases (4 men and 10
women; 22-75 years of age, mean ± SD: 33.2 ± 15.5)
and 23 normal control subjects (NC) without allergic
symptoms (15 men and 8 women; 22-44 years of age,
mean ± SD: 26.2 ± 6.5) were recruited as volunteers
and included in this study. The severity of AD was
evaluated using severity index of Japanese guideline
for AD.3 This study was carried out in accordance
with the guidelines stated in the Declaration of Hel-
sinki and was approved by the Ethics Committee of
Hiroshima University Institute of Biomedical &
Health Sciences (Approved No 556, 630). Written in-
formed consent was obtained from every subject.
PREPARATION OF PURIFIED MGL_1304 (QRX)
AND RECOMBINANT MGL_1304
The semi-purified sweat antigen purified from human
sweat of healthy volunteers described in the previous
report,13 QR (semi-purified sweat antigen), was used
for histamine release test (HRT). QR was further frac-
tionated by a gel chromatography column, and the
fractions with histamine releasing activity were col-
lected as purified MGL_1304 (QRX) as described pre-
viously.15 QRX was used for immunoblot analysis and
ELISA.
By using Escherichia coli (JM109) and pCold TF
vectors coding MGL_1304, the poly histidine-tagged
and trigger factor (TF)-fused rMGL_1304 protein
(TF-rMGL_1304) was prepared as described previ-
ously.15
MONOCLONAL ANTIBODY AGAINST PURIFIED
MGL_1304 (QRX)
A mouse monoclonal antibody, Smith-2,15 which has
neutralization ability against histamine release activ-
ity from basophils of patients with AD in response to
QRX, was used for ELISA measuring QRX-specific
IgE.
WESTERN BLOT ANALYSIS
Samples were loaded into a SDS-PAGE gel and trans-
ferred to a polyvinylidene fluoride (PVDF) mem-
brane as reported elsewhere.16 The membranes were
incubated with AD standard serum or anti-penta-His
antibody (Qiagen, Hilden, Germany) at 4℃ over-
night. The membrane bound primary antibodies were
visualized with horseradish peroxidase-conjugated
secondary antibodies and chemiluminescence.
HISTAMINE RELEASE TEST
HRT with basophils obtained from peripheral blood
were performed as described previously.17 Cells were
stimulated with 1 μgml of goat anti-human IgE anti-
body (Bethyl Laboratories, Montgomery, TX, USA)
and 33 ngml of QR.
ESTABLISHMENT OF ELISA SYSTEMS FOR
MEASUREMENT OF MGL_1304-SPECIFIC IMMU-
NOGLOBULINS
To quantify the amount of MGL_1304-specific immu-
noglobulins, the AD standard serum was prepared by
pooling sera of 20 patients with AD whose basophils
release histamine in response to QR.
Ninety-six well ELISA-plates (High-Binding, Grei-
ner bio-one, Frickenhausen, Germany) were used for
all ELISA. For the measurement of QRX-specific IgE,
96 well plates were directly coated with 1 μgml QRX
for direct ELISA or 10 μgml Smith-2 antibody for
sandwich ELISA in phosphate buffered saline (PBS)
without any carrier proteins and incubated over night
at 4℃. The remaining non-specific binding sites were
blocked with 2% bovine serum albumin PBS (BSA-
PBS) for 1 hour at room temperature. The plates
coated with Smith-2 antibody were sequentially incu-
bated with 1 μgml QRX in 0.1% BSA-PBS for 90 min-
utes at room temperature. The wells were incubated
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with 100 μl of patient sera diluted 1 : 40 with 1% BSA-
PBS at room temperature for 90 minutes and subse-
quently with peroxidase-labeled antibody to human
IgE (ε-chain specific) (KPL, Gaithersburg, MD, USA)
diluted 1 : 3000 with 1% BSA-PBS, at room tempera-
ture for 1 hour.
For the measurement of rMGL_1304-specific IgE,
96 well plates were directly coated with 3 μgml TF-
rMGL_1304 or the same concentration of TF alone di-
luted in PBS without carrier protein, and incubated
over night at 4℃. The remaining non-specific binding
sites were blocked with 2% BSA-PBS for 1 hour at
room temperature. The wells were incubated with
100 μl of patient sera diluted 1 : 20 with 1% BSA-PBS
at room temperature for 2 hours and subsequently
with peroxidase-labeled antibody to human IgE de-
scribed above and diluted 1 : 3000 with 1% BSA-PBS,
at room temperature for 1 hour.
For the measurement of rMGL_1304-specific IgG,
96 well plates were directly coated with 3 μgml TF-
rMGL_1304 or TF alone in PBS without carrier pro-
tein, at 4℃ over night. The remaining non-specific
binding sites were blocked with 5% skim-milk in PBS
(skim-milk-PBS) for 1 hour at room temperature. The
wells were incubated with 100 μl of patient sera di-
luted 1 : 200 in 1% skim-milk-PBS at room tempera-
ture for 2 hours and subsequently with peroxidase-
labeled antibody against human IgG (Fc specific)
(KPL) diluted 1 : 2000 in 1% skim-milk-PBS at room
temperature for 1 hour.
For the measurement of rMGL_1304-specific IgG4,
96 well plates were directly coated with 3 μgml TF-
rMGL_1304 or TF alone in PBS without carrier pro-
tein, and incubated over night at 4℃. The remaining
non-specific binding sites were blocked with 5% skim-
milk-PBS for 1 hour at room temperature. The wells
were incubated with 100 μl of patient sera diluted 1 :
20 with 1% skim-milk-PBS at room temperature for 2
hours and subsequently with peroxidase-labeled anti-
body to human IgG4 (γ4 chain specific) (Southern
Biotech) diluted 1 : 2500 with 1% skim-milk-PBS, at
room temperature for 1 hour.
All incubations were followed by three washes with
wash buffer (PBS with 0.05% Tween-20), and the anti-
body binding was visualized by incubation with TMB
Microwell Peroxidase Substrate and TMB Stop Solu-
tion (KPL). The optical density at 450 nm (OD450)
was then read with an automatic plate reader (Bench-
mark Plus, Bio-Rad, Hercules, CA, USA). When we
use TF-rMGL_1304 as an antigen, we calculated dif-
ferences between OD450 obtained with TF-rMGL_
1304 and that with TF alone. Samples were tested in
duplicate, and the concentrations of specific antibod-
ies (Unitsml) were calculated by using a standard
curve obtained from a serial dilution of the AD stan-
dard serum stated above. The units of each specific
antibody in one milliliter of the AD standard serum
were defined as 1000 Units.
MEASUREMENT OF MALASSEZIA-SPECIFIC IgE
AND TARC
Serum levels of Malassezia-specific IgE (UAml) and
TARC (pgml) were measured by using the Immuno-
CAP 100 instrument (Phadia AB, Portage, MI, USA)
and ELISA in SRL Inc. (Tokyo, Japan), respectively.
STATISTICAL ANALYSIS
Analyses were performed by the use of GRAPHPAD
PRISM version 5.04 (GraphPad Software, San Diego,
CA, USA). All data are presented as mean ± SEM.
RESULTS
ESTABLISHMENT OF THE ELISA SYSTEM FOR
IgE, IgG, AND IgG4 AGAINST MGL_1304
The semi-purified sweat antigen, QRX (17 kDa), TF
(60 kDa) and TF-rMGL_1304 (77 kDa) were detected
with immunoblots by using AD standard serum and
or anti-polyhistidine-tag antibody (Supplementary
Fig. 1). However, with a direct ELISA using QRX as a
coated antigen, we could hardly detect QRX-specific
IgE (Fig. 1a), IgG and IgG4 (data not shown). The
minimum detection limit of the sandwich ELISA for
QRX-specific IgE by using Smith2-antibody as a
coated (capture) antibody was greatly improved as
compared with the direct ELISA (Fig. 1a). In contrast
to IgE against QRX, IgG and IgG4 against QRX could
not be detected by the sandwich ELISA using Smith2-
antibody due to a cross activity of Smith2-antibody for
the secondary antibodies against human IgG and IgG
4 (data not shown). However, specific bindings to
rMGL_1304 by IgE, IgG and IgG4 were all success-
fully detected with the direct ELISA (Fig. 1b-d).
rMGL_1304-SPECIFIC IgE VS QRX-SPECIFIC IgE
The concentrations (Unitsml) of QRX-specific-IgE
and rMGL_1304-specific-IgE in sera of patients with
AD were highly correlated (Fig. 2a, R = 0.954, P <
0.0001, N = 63). The levels of QRX- or rMGL_1304-
specific IgE in sera and histamine release induced by
QR from basophils of the patients with AD were also
correlated (Fig. 2b, R = 0.778, P < 0.0001, N = 53)
(Fig. 2c, R = 0.783, P < 0.0001, N = 53). According to
the ROC curves of QRX-specific IgE or rMGL_1304-
specific IgE and HRT (Fig. 2d, e) among patients and
NC, we defined the cut off values as 53 Unitsml for
QRX specific-IgE (sensitivity 84.9%, specificity 85.7%,
P < 0.0001, N = 111), and 33.6 Unitsml for rMGL_
1304-IgE specific-IgE (sensitivity 81.8%, specificity
80.0%, P < 0.0001, N = 111).
LEVELS OF QRX- AND rMGL_1304-SPECIFIC IgE
IN PATIENTS WITH EACH DISEASE, AND COR-
RELATIONS WITH SEVERITY OF AD
The levels of QRX-specific IgE in sera of patients with
AD and those of patients with CU were significantly
higher than those of NC (P < 0.001, P < 0.05) and pa-
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Fig.　1　Standard curves of MGL_1304-specifi c immunoglobulins plotted by using AD standard se-
rum in ELISA. QRX-specifi c IgE in the serial diluted AD standard serum was measured by direct and 
sandwich ELISA (a). rMGL_1304-specifi c IgE (b), rMGL_1304-specifi c IgG (c), and rMGL_1304-
specifi c IgG4 (d) in the serial diluted AD standard serum were measured by direct ELISA. Each pan-
el showed a representative data expressed as means of OD450 values done in duplicate.
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tients with BA (P < 0.001, P < 0.01) (Fig. 3a). Like-
wise, the level of rMGL_1304-specific IgE in sera of
patients with AD was significantly higher than those
of NC (P < 0.05) and patients with BA (P < 0.001)
(Fig. 3b). The level of rMGL_1304 specific-IgE in
sera of patients with CU was significantly higher than
that with BA (P < 0.001), but not that of NC. Accord-
ing to the cut off values defined by ROC curves, the
rate of QRX-specific IgE-positive patients with AD
was significantly higher than those of NC (P < 0.01).
However, there were no significant differences be-
tween NC and CU in the rate of patients with positive
QRX-specific IgE and rMGL_1304-specific IgE in
sera, respectively (Table 1). Moreover, the rate of
rMGL_1304-specific IgE-positive patients with BA
was significantly lower than that in NC (P < 0.01).
Disease severities and the levels of QRX-specific IgE
and rMGL_1304-specific IgE in patients with AD were
significantly correlated (Fig. 3c, R = 0.5468, P <
0.0001) (Fig. 3d, R = 0.448, P < 0.0001).
LEVELS OF rMGL_1304-SPECIFIC IgG AND IgG4
IN PATIENTS WITH EACH DISEASE, AND COR-
RELATIONS WITH SEVERITIES OF AD
The levels of rMGL_1304-specific IgG in patients with
AD was significantly higher than that of BA (P <
0.01), but the difference in the levels of rMGL_1304-
specific IgG4 in patients with AD and those of the
other diseases was not apparent (Fig. 4a, b). The dis-
ease severities and the levels of rMGL_1304-specific
IgG and IgG4 in patients with AD were weakly but
significantly correlated (Fig. 4c, R = 0.3292, P =
0.0024) (Fig. 4d, R = 0.3823, P = 0.0004).
MGL_1304-SPECIFIC IgE IS CORRELATED WITH
rMGL_1304-SPECIFIC IgG AND IgG4 IN PA-
TIENTS WITH AD BUT NOT IN PATIENTS WITH
CU
The levels of rMGL_1304-specific IgE and rMGL_
1304-specific IgG or IgG4 in patients with AD were
significantly correlated (Fig. 5a, R = 0.469, P = 0.0002,
N = 60) (Fig. 5b, R = 0.511, P < 0.0001, N = 60). The
levels of total serum IgE and that of rMGL_1304-
specific IgE or QRX-specific IgE in patients with AD
were even more significantly correlated (Fig. 5c, R =
0.703, P < 0.0001, N = 49) (Fig. 5d, R = 0.697, P <
0.0001, N = 49). Moreover, the serum levels of QRX-
specific IgE and rMGL_1304-specific IgE in patients
with AD were weakly but significantly correlated with
serum TARC (Supplementary Fig. 2a, R = 0.266, P =
0.0367, N = 62) (Supplementary Fig. 2b, R = 0.300, P =
0.018, N = 62). However, no correlations were ob-
ELISA of Serum IgE against MGL_1304
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Fig.　2　Correlation between QRX-specifi c IgE, rMGL_1304-specifi c IgE, and basophil histamine re-
lease against QR. Levels of QRX- and rMGL_1304-specifi c IgE in sera of patients with AD (a). Hista-
mine releases of basophils induced by QR are correlated with serum levels of QRX-specifi c IgE (b) 
and rMGL_1304-specifi c IgE (c) in patients with AD. Histamine release was expressed as (net hista-
mine release induced by QR) / (net histamine release induced by anti-IgE) × 100 (%). ROC curves of 
QRX-specifi c IgE (d) and rMGL_1304-specifi c IgE (e) were created.
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tained between rMGL_1304-specific IgE and rMGL_
1304-specific IgG or IgG4, or between rMGL_1304
specific IgE or QRX-specific IgE and total serum IgE
in patients with CU (Fig. 6). No correlation was ob-
served between QRX-specific IgE or rMGL_1304 spe-
cific IgE and the number of peripheral eosinophils in
patients with CU (Supplementary Fig. 3).
MALASSEZIA-SPECIFIC IgE AND MGL_1304-
SPECIFIC IgE WERE CORRELATED, BUT NOT
COMPLETELY MATCHED
The levels of QRX-specific IgE or rMGL_1304-specific
IgE and the levels ofMalassezia-specific IgE were sig-
nificantly correlated (Fig. 7a, R = 0.729, P < 0.0001, N
= 59) (Fig. 7b, R = 0.730, P < 0.0001, N = 59), but not
completely matched in patients with AD. The levels
of Malassezia-specific IgE in patients with AD were
Hiragun M et al.
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Table　1　Number of patients with positive or negative QRX-specifi c IgE and rMGL_1304-specifi c IgE in each disease
QRX-specifi c IgE NC AD CU BA AR
Positive  6 42 13  6  7
Negative 17 21 11 26  7
Positive rate 26.1 66.7 56.5 18.8 50.0
P-value -  0.0012**  0.0753  0.5296  0.1713
rMGL_1304-specifi c IgE NC AD CU BA AR
Positive  9 39 14  2  4
Negative 14 24 10 30 10
Positive rate 39.1 61.9 58.3  6.3 28.6
P-value -  0.0857  0.2476  0.0048**  0.7245
Positive rates were compared with NC by Chi-square test. NC, normal controls; AD, atopic dermatitis; CU, cholinergic urticaria; BA, bron-
chial asthma; AR, allergic rhinitis. **P < 0.001.
Fig.　3　Comparisons of serum levels of QRX- and rMGL_1304-specifi c IgE among diseas-
es and correlations with severities of AD. Serum levels of QRX-specifi c IgE (a) and 
rMGL_1304-specifi c IgE (b) in patients with each disease were plotted and analyzed by 
Kruskal-Wallis test. The serum levels of QRX-specifi c IgE and rMGL_1304-specifi c IgE in 
patients showing various severities of AD were plotted and analyzed by Spearman rank cor-
relation (c, d). NC, normal controls; AD, atopic dermatitis; CU, cholinergic urticaria; BA, 
bronchial asthma; AR, allergic rhinitis. *P < 0.05, **P < 0.01, ***P < 0.001.
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also highly correlated with total serum IgE (Supple-
mentary Fig. 4a, R = 0.749, P < 0.0001, N = 0.46), and
weakly correlated with eosinophils (%) (Supplemen-
tary Fig. 4b, R = 0.283, P = 0.0491, N = 49).
DISCUSSION
In this study, we established ELISA systems to meas-
ure specific IgE, IgG and IgG4 against native and
ELISA of Serum IgE against MGL_1304
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Fig.　4　Serum levels of rMGL_1304-specifi c IgG and IgG4 in diseases and their correlations with 
severities of AD. Serum levels of rMGL_1304-specifi c IgG (a) and IgG4 (b) in each disease were 
plotted and analyzed by Kruskal-Wallis test. The serum levels of rMGL_1304-specifi c IgG (c) and 
IgG4 (d) in patients with various severities of AD were plotted and analyzed by Spearman rank 
correlation. *P < 0.05.
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*
rMGL_1304 in sera of patients with AD and other dis-
eases. MGL_1304 is a secretory protein of M. globosa
and a major antigen contained in human sweat and
highly induces histamine release from basophils of
many patients with AD.
By using a monoclonal antibody against purified
MGL_1304 (QRX), Smith2, as a capture antibody, we
could detect the specific IgE against QRX in sera of
patients with AD with a high sensitivity. We have al-
ready reported that IgE from patients with AD recog-
nized the steric structure, but not a short amino-acid
sequence of MGL_1304.15 The difficulty of the direct
ELISA using QRX might be due to its antigenic prop-
erty. In contrast to QRX, TF-rMGL_1304 could be ap-
plied to the direct ELISA to measure rMGL_1304-
specific IgE, IgG and IgG4 without the capture anti-
body. This advantage of TF-rMGL_1304 over QRX
could be due to the tag protein andor TF that might
‘raise’ MGL_1304 on the ELISA plate so as to make
its epitope more easily accessible by human antibod-
ies. Moreover, data of QRX-specific IgE and rMGL_
1304-specific IgE in sera of patients with AD are
highly correlated. However, QRX specific-IgE
showed higher sensitivity and specificity against HRT
than rMGL_1304. Such differences may be due to a
post-translational modification of native MGL_1304 in
QRX, but which is lacked by rMGL_1304 synthesized
by Escherichia coli. Since, QRX is purified from sweat
of human volunteers, it is extremely scarce and diffi-
cult to obtain in sufficient amounts for assays in rou-
tine clinical practices. We are currently establishing a
method to purify large amounts of native MGL_1304
from culture supernatant ofM. globosa.
In patients with AD, the serum levels of specific
IgE against MGL_1304 were significantly higher than
those of NC. Moreover, the levels of MGL_1304-
specific IgE in patients with AD were well correlated
with disease severities of AD and serum levels of total
IgE. These results indicate that the measurement of
MGL_1304-specific IgE is useful not only to evaluate
the allergy to MGL_1304 in sweat but also to evaluate
the disease severity of AD. However, serum levels of
MGL_1304-specific IgE showed only a weak correla-
tion with serum TARC. It might be due to more rapid
changes of TARC than MGL_1304-specific IgE in as-
sociation with disease severities.3,18 Therefore, the
levels of QRX- and rMGL_1304-specific IgE are likely
more suitable for the evaluation of long-term disease
Hiragun M et al.
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Fig.　5　Correlations among rMGL_1304-specifi c immunoglobulins in sera of patients with AD. 
Signifi cant correlations were observed between serum levels of rMGL_1304-specifi c IgE and 
rMGL_1304-specifi c IgG (a), rMGL_1304-specifi c IgG4 (b), or total IgE (c) in patients with AD. The 
levels of serum total IgE were also signifi cantly correlated with QRX-specifi c IgE (d) in patients 
with AD.
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severities rather than short-term disease activities of
AD. The presence of serum IgG against sweat anti-
gens, were suggested by our previous study using
histamine release-neutralization assay.17 However,
there were no significant differences between the lev-
els of rMGL_1304-specific IgG or IgG4 in patients
with AD and those of NC. These results suggest that
both patients with AD and healthy individuals may be
sensitized with MGL_1304, but IgE class switching
against MGL_1304 occurs much more strongly in pa-
tients with AD than in NC, although the opportunity
of sensitization with MGL_1304 exists even in normal
controls. Thus, for the patients with AD, the measure-
ment of IgE against MGL_1304 is more important
than that of IgG or IgG4 against rMGL_1304.
The influence of Malassezia species on the patho-
genesis of AD has attracted attention in recent years.
Many studies have shown the effectiveness of anti-
fungal therapy on AD with Malassezia allergy,19 and
the association of high levels of Malassezia-specific
IgE and severe AD.20,21 Ishibashi et al. identified 42
kDa protein (MGp42) as a major antigen of M. glo-
bosa for serum IgE of patients with AD.22 Moreover,
Darabi et al.19 reported that the peripheral blood
mononuclear cells of patients with AD who have spe-
cific IgE againstMalassezia showed an increased pro-
liferation and an increased production of inflamma-
tory cytokines upon the exposure to Malassezia com-
pared with cells from healthy control subjects.
The identification of MGL_1304 as a histamine re-
leasing antigen in human sweat has revealed the in-
volvement of M. globosa in type 1 allergy against
sweat observed in patients with AD andor CU. How-
ever, western blotting by using sera of patients with
AD for lysates or culture supernatant of M. globosa
shows many bands including MGp42,15,22 whereas
patients with AD react to the fractions of sweat eluted
between molecular markers of 17 kDa and 1.35 kDa
by gel chromatography.9 Moreover, in the present
study, serum levels of MGL_1304-specific IgE and
Malassezia-specific IgE were not completely matched,
suggesting that the importance of MGL_1304-specific
IgE rather than IgE against the whole Malassezia an-
tigens in patients whose symptoms are exacerbated
by sweating.
The relationship between MGL_1304 and CU is in-
ELISA of Serum IgE against MGL_1304
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Fig.　6　Correlations among rMGL_1304-specifi c immunoglobulins in sera of patients with CU. No 
signifi cant correlations was observed between serum levels of rMGL_1304-specifi c IgE and IgG 
(a), IgE and IgG4 (b) or the specifi c IgE and total serum IgE (c). Likewise, no apparent correlation 
was observed between serum levels of QRX-specifi c IgE and total serum IgE in patients with CU (d).
Total IgE (Log10 IU/ml)
Q
R
X
-s
pe
ci
fic
 Ig
E
(L
og
10
 U
ni
ts
/m
l)
0 1 2 3 4
3
2
1
0
Total IgE (Log10 IU/ml)
rM
G
L_
13
04
-s
pe
ci
fic
 Ig
E
(L
og
10
 U
ni
ts
/m
l)
0 1 2 3 4
3
2
1
0
rMGL_1304-specific IgG4
(Log10 Units/ml)
rM
G
L_
13
04
-s
pe
ci
fic
 Ig
E
(L
og
10
 U
ni
ts
/m
l)
0 1 2 3 4
rMGL-1304-specific IgG
(Log10 Units/ml)
rM
G
L_
13
04
-s
pe
ci
fic
 Ig
E
(L
og
10
 U
ni
ts
/m
l)
0 1 2 3 4
4
3
2
1
0
4
3
2
1
0
a b
N = 24
R = 0.0871
P = 0.6856
N = 24
R = 0.140
P = 0.515
N = 16
R = 0.384
P = 0.1418
N = 16
R = 0.316
P = 0.2329
c d
Fig.　7　Correlation between serum levels of MGL_1304-specifi c IgE and Malassezia-specifi c IgE. 
Serum levels of Malassezia-specifi c IgE and QRX-specifi c IgE (a) or rMGL_1304-specifi c IgE (b) in 
patients with AD were signifi cantly correlated.
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triguing. In the present study, we revealed that the
levels of QRX specific-IgE in patients with CU were
also higher than that of NC and BA. Takahagi et al.14
also reported that the levels of basophils histamine
release against QR in patients with CU were signifi-
cantly higher than that of NC. On the other hand, the
levels of rMGL_1304 specific-IgG or IgG4 in patients
with CU were not correlated with their levels of QRX-
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or rMGL_1304-specific IgE. Taking into account that
both IgG and IgG4 against MGL_1304 likely neutral-
ize the histamine release activity of MGL_1304, the
presence of IgE over IgG and IgG4 in their binding
activity to MGL_1304 may be critical in the patho-
genesis of CU. Several groups have already per-
formed clinical trials of hyposensitization therapy for
CU by the use of autologous sweat.23-25 Moreover, it
is known that antigen-specific immunotherapy for al-
lergic rhinitis induces the increase of antigen-specific
IgG4.26,27 Therefore, the methods to evaluate levels
of serum IgG or IgG4 against MGL_1304 might be
useful to monitor the effectiveness of immunotherapy
on patients with CU.
The levels of QRX specific-IgE in patients with AR
tended to be higher than that of NC, although this dif-
ference was not statistically significant. It might be
due to the colonization of M. globosa in nasal cavity,28
and suggests that MGL_1304 might also be a causa-
tive antigen for a certain population of patients with
AR.
In conclusion, MGL_1304 is an important antigen
in sweat and the methods to quantify the specific IgE
against MGL_1304 in sera by ELISA were a useful
means to diagnose allergy to MGL_1304 contained in
sweat and estimate long term disease severities of
AD. The measurement of QRX-specific IgE in pa-
tients with CU was also useful for the diagnosis and
could be a clue to clarify the mechanism of CU. Fur-
ther studies on the relationship between AD or CU
and MGL_1304 in sweat are needed.
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